Publications by authors named "Merle P"
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (PVTT) and other high-risk prognostic factors are reported.
Methods: IMbrave150 was a global, randomized (2:1), open-label, phase 3 study in systemic treatment-naive patients with unresectable HCC; OS and PFS were co-primary endpoints.
The COVID-19 pandemic was an unprecedented threat to global health. During times of public health crises, governments and healthcare practitioners must effectively communicate preventive guidelines to the public to reduce viral transmission. Public compliance with recommended health behaviours is essential to the success of the overall pandemic response.
View Article and Find Full Text PDFArticle Synopsis
- Congenital myasthenic syndromes (CMS) are genetic disorders that impact neuromuscular transmission, primarily identified in childhood but often diagnosed in adulthood, leading to challenges in management.
- A study of 235 adult CMS patients in France revealed diverse genetic mutations and highlighted the need for ongoing care, as the prognosis and long-term outcomes remain unclear.
- The research categorized patients based on the initial symptoms and found varied disease progression patterns, with certain genotypes showing higher rates of ICU admission and the stability of phenotypical features across a patient's life.
Previous health communication research has demonstrated the negative psychological and health effects of depicting thin-sized models in mass media advertisements including on social media sites such as Instagram. However, gym advertisements are one common source for the presentation of lean and thin-sized models on Instagram. Therefore, the current study guided by social comparison theory and signaling theory aimed to experimentally examine the effect of thin-sized models relative to plus-sized models as well as slogan-type (health and wellness versus physique-based) on women's appearance comparison, body satisfaction, perceived gym fit, and intentions to join the gym.
View Article and Find Full Text PDFIntroduction: The prognosis of metastatic non-small cell lung cancer (NSCLC) has been improved by the use of immune checkpoint inhibitors (ICI). Unfortunately, in some cases, cancer cells will develop resistance mechanisms. In case of progression in a limited number of lesions (oligoprogression), focal treatment with radiotherapy is proposed while continuing the ICI therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of percutaneous radiofrequency ablation (RFA) for treating intrahepatic cholangiocarcinomas (iCCA) by analyzing patient data from 2000 to 2022.
- It finds that multibipolar RFA has a lower local recurrence rate compared to monopolar RFA (22% vs. 55%) and suggests that tumor size and liver health significantly impact survival outcomes.
- The results indicate that patients with iCCA experience shorter overall survival than those with hepatocellular carcinoma (26 vs. 68 months), and highlight the importance of considering adjuvant chemotherapy due to high rates of distant metastases.
Background: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up.
View Article and Find Full Text PDFIn France, about 2000 new cases of anal cancer are diagnosed annually. Squamous cell carcinoma is the most common histological type, mostly occurring secondary to persistent HPV16 infection. Invasive cancer is preceded by precancerous lesions.
View Article and Find Full Text PDFBackground: Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma.
Methods: In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites.
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported.
Methods: Adults with sorafenib-treated advanced HCC were randomized 2:1 to pembrolizumab 200 mg intravenously every 3 weeks or placebo.
Introduction: We conducted a systematic literature review to assess the utility of liver function assessments for predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma (aHCC).
Methods: This was a PRISMA-standard review and was registered with PROSPERO (CRD42021244588). MEDLINE and Embase were systematically searched (March 24, 2021) to identify publications reporting the efficacy and/or safety of systemic anticancer therapy (vs.
Background: Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab,based on landmarkclinical trials.
Methods: IFCT-1905 CLINATEZO is a nationwide, non-interventional, retrospectivestudy of patients with extensive-SCLC receivingatezolizumab plus chemotherapy as part of French Early Access Program.
Background: Current staging systems for hepatocellular carcinoma (HCC) still have limitations in clinical practice. Our study aimed to explore the prognostic factors and develop a new nomogram to predict the cancer-specific survival (CSS) for patients with HCC.
Methods: A total of 6,166 HCC patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database.
Article Synopsis
- The ELITor study analyzed real-world data from the CHIEF cohort to understand treatment patterns and patient characteristics for unresectable hepatocellular carcinoma in France, focusing on sociodemographic, clinical, and quality of life factors.
- A total of 367 patients were included, with most presenting at advanced BCLC C stage and a high prevalence of cirrhosis; alcohol was identified as the main cause of the disease.
- Results showed that tyrosine-kinase inhibitors were the most common systemic treatment, and patients receiving atezolizumab plus bevacizumab demonstrated better health statuses, although many experienced a decline in health quality post-treatment.
Article Synopsis
- This study evaluated the effectiveness and safety of second-line tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC) who previously progressed after treatment with atezolizumab and bevacizumab.
- A total of 82 patients were analyzed, with those receiving regorafenib showing significantly better overall survival (OS) compared to other TKIs like sorafenib, lenvatinib, and cabozantinib.
- Safety results indicated that 20% of patients experienced grade 3 adverse events, but there were no severe grade 4 or 5 events reported.
Background: Atezolizumab plus Bevacizumab combination therapy has recently emerged as the new standard of care for unresectable HCC. Significant tumor burden reduction can be observed under that treatment, raising the question of liver transplantation (LT). The safety of another immune checkpoint inhibitor (ICI), nivolumab, is unclear in the pre-transplant setting.
View Article and Find Full Text PDFIntroduction: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choice between the two treatments.
Methods: We conducted an anchored matching-adjusted indirect comparison using individual patient data from the RESORCE trial of regorafenib and published aggregate data from the CELESTIAL trial of cabozantinib.
Article Synopsis
- Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme lysosomal acid alpha-glucosidase, and enzyme replacement therapy (ERT) is the only treatment available to manage this condition.
- This study focused on managing infusion-associated reactions (IAR) in late-onset Pompe disease patients in France, analyzing data from 115 patients treated between 2006 and 2020, where 15 experienced at least one hypersensitivity reaction.
- The findings indicate that ERT can be safely reintroduced using premedication, modified regimens, or desensitization protocols, even in patients with severe reactions or high antibody levels.
Purpose: In early-stage hepatocellular carcinoma (HCC) patients merely fit for surgery, transarterial chemoembolization (TACE) achieve low long-term disease control. We evaluated the efficacy and safety of its combination with moderately hypofractionated radiotherapy (hRT) using RTF3 regimen.
Material And Methods: Between 2006 and 2016, 61 consecutive patients treated in our single expert center for a Barcelona Clinic Liver Cancer (BCLC) A HCC by TACE followed by hRT 3Gy/fraction were retrospectively included.
Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma.
Hepatobiliary Surg Nutr
April 2023
Individuals who report perceived stress often eat more unhealthy foods and more calories than those with lower stress levels, though individual differences and contexts are important. This study investigated how visual food cues on fast-food menus may increase calorie consumption intentions due to their potential motivational influences. A 2 (presence or absence of visual cues) x 4 (exemplar fast-food restaurant menu) fractionated experiment administered online (N = 325) indicated that when participants viewed menus with visual cues, they selected a greater number of calories to consume.
View Article and Find Full Text PDFObjective: It is unknown whether hepatitis C virus (HCV)-cured people with HIV (PWH) without cirrhosis reached the same mortality risk as HCV-uninfected PWH. We aimed to compare mortality in PWH cured of HCV by direct-acting antivirals (DAAs) to mortality in individuals with HIV monoinfection.
Design: Nationwide hospital cohort.
Article Synopsis
- Transcatheter arterial chemoembolisation (TACE) is used for treating liver cancer patients who can't undergo curative therapies; this study compared TACE alone with TACE combined with external conformal radiotherapy (CRT).
- The trial involved 120 participants, mostly older males with alcohol-related liver issues, and aimed to assess liver progression-free survival (PFS) over 12 and 18 months.
- Results indicated that while the combined treatment (TACE + CRT) showed better local control, it did not significantly improve PFS or overall survival compared to TACE alone, and led to more serious liver-related side effects.
Article Synopsis
- Tislelizumab, an antibody targeting the PD-1 protein, showed some effectiveness and safety for treating advanced hepatocellular carcinoma (HCC) in patients who had received prior therapies.
- In a phase 2 study involving 249 patients, the objective response rate (ORR) was 13%, with a disease control rate of 53% and a median overall survival of 13.2 months.
- Side effects were mostly manageable, with only 15% of patients experiencing severe treatment-related adverse events, and no treatment-related deaths reported.
Article Synopsis
- * The TRIPLET-HCC trial is a phase II-III study that aims to evaluate the efficacy and safety of adding ipilimumab to the current double therapy of atezolizumab and bevacizumab for patients with specific types of HCC.
- * The trial's primary goals are to compare the objective response rates and overall survival between the triple and double therapy groups, while also examining progression-free survival, patient tolerance, quality